Potentially the response to ADT could also be followed, assuming that regression of the tumour resulted in less/no expression of the biomarkers, but the loss of expression could also be because of the reduced expression of androgen-responsive genes, like TMPRSS2 and PCA3 (Tomlins et al, 2005; Shaw et al, 2007). This evidence concerns the gene PCA3 and neoplasm.